Irritable Bowel Syndrome |
| |
Authors: | Sach Joel A. Chang Lin |
| |
Affiliation: | UCLA/CURE Neuroenteric Disease Program, 11301 Wilshire Blvd Bldg 115, Room 213, Los Angeles, CA 90073, USA. E-mail: joelsach@yahoo.com |
| |
Abstract: |
– | Because treatment of irritable bowel syndrome (IBS) patients can be frustrating to the clinician and patient as well, the physician should strive to gain the patient’s confidence with a concise, appropriate work-up and by offering reassurance and education that IBS is a functional disorder without significant long-term health risks. | – | First-line treatment should be aimed at treating the most bothersome symptom. | – | Tricyclic antidepressants are superior to placebo in reducing abdominal pain scores, as well as improving global symptom severity [1••]. | – | Loperamide is superior to placebo in managing IBS-associated diarrhea [2••]. | – | Whereas fiber has a role in treating constipation, its value for IBS or, specifically, in the relief of abdominal pain or diarrhea associated with IBS is controversial [2••]. | – | Although certain antispasmodics have demonstrated superiority over placebo in managing abdominal pain, none of these agents are available in the United States [3••]. | – | Probiotic therapy using Lactobacillus plantarum has demonstrated superiority to placebo in improving pain, regulating bowel habits, and decreasing flatulence [4]. | – | As studied in a recent placebo-controlled prospective study, Chinese herbal medicines significantly improved bowel symptom scores and global symptom profile, and reduced IBS-related quality of life impairment [5]. | – | Some of the most promising emerging therapies in IBS revolve around targeted pharmacotherapeutic modulation of serotonin receptors (ie, 5-HT3 and 5-HT4 subtypes), which are involved in sensory and motor functions of the gut. Other investigational agents that are also being explored include cholecystokinin antagonists, α2-adrenergic agonists (eg, clonidine), serotonin reuptake inhibitors (eg, citalopram), and neurokinin antagonists [6]. | – | IBS is best understood through the biopsychosocial paradigm, and therefore, its effective management requires a comprehensive multidisciplinary approach based on patient education and reassurance, enhanced by diet recommendations and lifestyle modifications, and complemented by pharmacotherapy and psychosocial intervention in more severe cases. | |
| |
Keywords: | |
本文献已被 PubMed SpringerLink 等数据库收录! |
|